OXOMEMAZINE


Synonyms	6487-RP 6847-RP Doxergan Dysedon Exe-top Imakol Oplex Oxomemazine RP 6847 RP-6847 Trimeprazine 5,5-dioxide
Status
Molecule Category	UNKNOWN
ATC	R06AD08
UNII	Q824SGH3RN
EPA CompTox	DTXSID5023405


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	QTQPVLDZQVPLGV-UHFFFAOYSA-N
Smiles	CC(CN(C)C)CN1c2ccccc2S(=O)(=O)c2ccccc21
InChI	InChI=1S/C18H22N2O2S/c1-14(12-19(2)3)13-20-15-8-4-6-10-17(15)23(21,22)18-11-7-5-9-16(18)20/h4-11,14H,12-13H2,1-3H3

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C18H22N2O2S
Molecular Weight	330.45
AlogP	3.17
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	4.0
Polar Surface Area	40.62
Molecular species	NEUTRAL
Aromatic Rings	2.0
Heavy Atoms	23.0

Related Entries

Cross References

Resources	Reference
ChEBI	135408
ChEMBL	CHEMBL2104734
DrugBank	DB13820
DrugCentral	2025
FDA SRS	Q824SGH3RN
Human Metabolome Database	HMDB0240230
PubChem	19396
SureChEMBL	SCHEMBL423634

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).